Excess Health Care Costs of Obesity in Adults with Diabetes Mellitus: a Claims Data Analysis

Abstract

Background Body weight management is a key factor in diabetes mellitus. However, both behavioral and pharmacological innovations to manage obesity may imply additional costs. In order to provide further insights into the role of obesity in diabetes-associated resource consumption, this study aims to estimate incremental costs of concomitant obesity in German adult patients (≥ 18 years) with different types of diabetes.

Methods Adopting a third-party payer perspective, claims data from a German statutory sickness fund (N=1 094 496) were analyzed for costs of annual drug prescriptions and out- and inpatient care in adult beneficiaries with diabetes in 2004. Using diagnostic information, 37 570 beneficiaries with diabetes were identified. Concomitant obesity was assessed by ICD-10-codes (E66) in the claims data. Adjusting for sex, age, and micro- and macro-vascular complications, one generalized gamma regression model with the log link was performed for type 2 diabetes patients (N=24 562), type 1 diabetes patients (N=5 663), and an unclassified group (N=7 345), respectively.

Results Overall, 33% of the patients with diabetes were identified as obese (type 2 diabetes: 34%, type 1 diabetes: 20%, unclassified: 38%). Affirming descriptive analyses, the generalized gamma regression models revealed that obesity is associated with significant increments in health care costs regardless of type of diabetes (type 2 diabetes: € 454, type 1 diabetes: € 812, unclassified: € 532). The interaction of obesity and macro-vascular complications was numerically stronger in type 1 than in type 2 diabetes but reached statistical significance only in type 2 diabetes (and the unclassified group). Moreover, concurrent macro- and micro-vascular complications were associated with higher incremental costs in all groups.

Conclusions Concomitant obesity is independently associated with incremental health care costs in adult patients with type 2 diabetes and, even more so, type 1 diabetes. Results are discussed with respect to the fact that in this sample, concurrent micro- and macro-vascular complications were more frequent in type 1 diabetes. At any rate, in light of these health care costs, obesity seems relevant in both types of diabetes. Due to claims data limitations, it was not possible to distinguish obesity classes based on body height and weight information. Further research should identify adiposity thresholds for increased resource consumption using both primary and secondary data.

Key words

diabetes mellitus - obesity - health care costs - insurance, health, reimbursement - insurance claim review

References

• 1 American Diabetes Association . Standards of medical care in diabetes – 2007.  Diabetes Care. 2007;  30 S4-S41
• 2 Ryden L, Standl E, Bartnik M. et al . Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD): Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary.  Eur Heart J. 2007;  28 88-136
• 3 Matthaei S, Bierwirth R, Fritsche A. et al . Behandlung des Diabetes mellitus Typ 2.  In German. Diabetologie. 2009;  4 S138-S143
• 4 Wing RR, Goldstein MG, Acton KJ. et al . Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity.  Diabetes Care. 2001;  24 117-123
• 5 Norris SL, Zhang X, Avenell A. et al . Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.  Cochrane Database Syst Rev. 2005;;  ((1):) CD004096
• 6 Kennedy RL, Khoo EY. New options for drug treatment of obesity in patients with Type 2 diabetes.  Diabet Med. 2005;  22 (S 04) 23-26
• 7 Barnett A, Allsworth J, Jameson K. et al . A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.  Curr Med Res Opin. 2007;  23 1493-1507
• 8 Kendall DM, Riddle MC, Rosenstock J. et al . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.  Diabetes Care. 2005;  28 1083-1091
• 9 Viswanathan P, Chaudhuri A, Bhatia R. et al . Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.  Endocr Pract. 2007;  13 444-450
• 10 Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. . Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience (1983-2005).  Arch Intern Med. 2009;  169 1307-1316
• 11 Martin S, Dreyer M, Kiess W. et al . Behandlung des Diabetes mellitus Typ 1.  In German. Diabetologie. 2009;  4 S136-S137
• 12 Conway B, Miller RG, Costacou T. et al . Adiposity and mortality in type 1 diabetes.  Int J Obes. 2009;  33 796-805
• 13 Delahanty LM, Nathan DM, Lachin JM. et al . Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial.  Am J Clin Nutr. 2009;  89 518-524
• 14 The Diabetes Control and Complications Trial Research Group . Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial.  Diabetes Care. 2001;  24 1711-1721
• 15 Williams KV, Erbey JR, Becker D. et al . Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes: The Epidemiology of Diabetes Complications Study.  Diabetes Care. 1999;  22 1084-1091
• 16 Renders CM, Valk GD, Griffin S. et al . Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings.  Cochrane Database Syst Rev. 2000;;  ((4)) CD001481
• 17 Clark M. Is weight loss a realistic goal of treatment in type 2 diabetes? The implications of restraint theory.  Patient Educ Couns. 2004;  53 277-283
• 18 Barnett A, Allsworth J, Jameson K. et al . A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.  Curr Med Res Opin. 2007;  23 1493-1507
• 19 Liatis S, Thomakos P, Papaoikonomou S. et al . Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 & 2006).  Exp Clin Endocrinol Diabetes. 2009;  117 505-510
• 20 Stock SAK, Redaelli M, Wendland G. et al . Diabetes – prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.  Diabet Med. 2005;  23 299-305
• 21 Jönsson B. Revealing the cost of type II diabetes in Europe.  Diabetologia. 2002;  45 S5-S12
• 22 Köster I, von Ferber L, Ihle P. et al . The cost burden of diabetes mellitus: the evidence from Germany – the CoDiM Study.  Diabetologia. 2006;  49 1498-1504
• 23 von Ferber L, Köster I, Hauner H. Medical costs of diabetic complications total costs and excess costs by age and type of treatment: results of the German CoDiM Study.  Exp Clin Endocrinol Diabetes. 2007;  115 97-104
• 24 Gandra SR, Lawrence LW, Parasuraman BM. et al . Total and component health care costs in a non-medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.  J Manag Care Pharm. 2006;  12 546-554
• 25 Ettaro L, Songer TJ, Zhang P. et al . Cost-of-illness studies in diabetes mellitus.  Pharmacoeconomics. 2004;  22 149-164
• 26 Finkelstein EA, Brown DS, Trogdon JG. et al . Age-specific impact of obesity on prevalence and costs of diabetes and dyslipidemia.  Value Health. 2007;  10 S45-S51
• 27 Krauth C, Hessel F, Hansmeier T. et al . Empirical standard costs for health economic evaluation in Germany – a proposal by the Working Group Methods in Health Economic Evaluation).  In German. Gesundheitswesen. 2005;  67 736-746
• 28 Federal Statistical Office .Diagnosedaten der Patienten und Patientinnen in Krankenhäusern (einschl. Sterbe- und Stundenfälle) In German.. Wiesbaden: Federal Statistical Office; 2005
• 29 Federal Ministry of Health and Social Security .Statistisches Taschenbuch 2004: Arbeits- und Sozialpolitik. In German. Bonn; Federal Ministry of Health and Social Security; 2005
• 30 Federal Statistical Office .Statistisches Jahrbuch 2004. In German. Wiesbaden; Federal Statistical Office; 2005
• 31 Federal Statistical Office .Diagnosedaten der Patienten und Patientinnen in Vorsorge- und Rehabilitationseinrichtungen 2004. In German. Wiesbaden; Federal Statistical Office; 2006
• 32 Federal Statistical Office .Gesundheit: Ausgaben, Krankheitskosten und Personal 2004. Presseexemplar. In German. Wiesbaden; Federal Statistical Office; 2006
• 33 Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models.  J Health Serv Res Policy. 2004;  9 197-204
• 34 Dodd S, Bassi A, Bodger K. et al . A comparison of multivariable regression models to analyse cost data.  J Eval Clin Pract. 2006;  12 76-86
• 35 Manning WG. Modeling Costs with Generalized Gamma Regression. .  http://www.spc.uchicago.edu/prc/pdfs/mannin02.pdf (last visited 8/28/2009)
• 36 Manning WG, Mullahy J. Estimating log models: to transform or not to transform?.  Journal of Health Economics. 2001;  20 461-494
• 37 Bramlage P, Wittchen HU, Pittrow D. et al . Recognition and management of overweight and obesity in primary care in Germany.  Int J Obes Relat Metab Disord. 2004;  28 1299-1308
• 38 von Lengerke T, Reitmeir P, John J. Direct medical costs of (severe) obesity: a bottom-up assessment of over- vs. normal-weight adults in the KORA-Study Region (Augsburg, Germany)).  In German. Gesundheitswesen. 2006;  68 110-115
• 39 Andreyeva T, Sturm R, Ringel JS. Moderate and severe obesity have large differences in health care costs.  Obes Res. 2004;  68 1936-1943
• 40 Pyörälä K, Lehto S, De Bacquer D. et al . EUROASPIRE I and II Groups: Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I and II surveys.  Diabetologia. 2004;  47 1257-1265
• 41 Rathmann W, Haastert B, Icks A. et al . High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA survey 2000.  Diabetologia. 2003;  46 182-189
• 42 Klauber J, Robra B-P, Schellschmidt H. editors. Krankenhaus-Report 2007. Schwerpunkt: Krankenhausvergütung – Ende der Konvergenzphase?. In German Stuttgart; Schattauer; 2008
• 43 von Lengerke T, John J, Mielck A. KORA Study Group . Excess direct medical costs of severe obesity by socioeconomic status in German adults.  Psychosoc Med. 2010;  7 Doc01
• 44 Wittek A, Sokalski B, Grzeszczak W. et al . Prevalence of diabetes and cardiovascular risk factors of industrial area in southern Poland.  Exp Clin Endocrinol Diabetes. 2009;  117 350-353
• 45 Li J, Bergmann A, Reimann M. et al . A more simplified Finnish diabetes risk score for opportunistic screening of undiagnosed type 2 diabetes in a German population with a family history of the metabolic syndrome.  Horm Metab Res. 2009;  41 98-103
• 46 Schwarz PE, Lindström J, Kissimova-Scarbeck K. et al . DE-PLAN project. The European perspective of type 2 diabetes prevention: diabetes in Europe – prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project.  Exp Clin Endocrinol Diabetes. 2008;  116 167-172
• 47 Schwarz PE, Li J, Lindstrom J. et al . Tools for predicting the risk of type 2 diabetes in daily practice.  Horm Metab Res. 2009;  41 86-97
• 48 Cawley J, Prinz T, Beane S. New York State Bariatric Surgery Workgroup . Health insurance claims data as a means of assessing reduction in co-morbidities 6 months after bariatric surgery.  Obes Surg. 2006;  16 852-858
• 49 Happich M, Reitberger U, Breischeidel L. et al . The economic burden of diabetic retinopathy in Germany in 2002.  Graefe's Arch Clin Exp Ophtahlmol. 2008;  246 151-159
• 50 Legato MJ, Gelzer A, Goland R. et al . Writing Group for The Partnership for Gender-Specific Medicine: Gender-specific care of the patient with diabetes: review and recommendations.  Gend Med. 2006;  3 131-158
• 51 Wadén J, Tikkanen H, Forsblom C. et al . Leisure time physical activity is associated with poor glycemic control in type 1 diabetic women: the FinnDiane study.  Diabetes Care. 2005;  28 777-782
• 52 Yu AP, Wu EQ, Birnbaum HG. et al . Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.  Curr Med Res Opin. 2007;  23 2157-2169

Correspondence